OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Price, News & Analysis $0.16 0.00 (0.00%) As of 10/5/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Arch Therapeutics Stock (OTCMKTS:ARTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arch Therapeutics alerts:Sign Up Key Stats Today's Range$0.16▼$0.1650-Day Range$0.16▼$0.1652-Week Range$0.16▼$1.57VolumeN/AAverage Volume4,068 shsMarket Capitalization$762.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arch Therapeutics, Inc. is a biotechnology company focused on developing products for wound care, tissue repair and bleeding control. Its platform is based on self-assembling peptide technology, which is designed to form a protective barrier over tissue when applied to a wound or surgical site. The company’s product portfolio has included AC5, a topical hemostatic and wound-management product intended to help control bleeding and protect injured tissue. Arch Therapeutics has also developed product variants for specific clinical applications, including surgical and gastrointestinal procedures, as well as products aimed at veterinary and other wound-care markets. The company’s products are intended for use by healthcare professionals rather than as systemic medicines. Arch Therapeutics was founded in 2006 and is headquartered in Framingham, Massachusetts. Its development and commercialization efforts have focused primarily on the United States, with the company also pursuing opportunities in international markets. The company has been led by Terrence W. Norchi, M.D., who has served as president and chief executive officer.AI Generated. May Contain Errors. Read More Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTH Stock News HeadlinesArch Therapeutics Inc. (ARTH) Product Pipeline Analysis, 2025 UpdateAugust 9, 2025 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)October 1, 2024 | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Chicago biotech-focused VC firm Arch Venture Partners closes $3 billion fundSeptember 27, 2024 | bizjournals.comArch Therapeutics, Inc. (ARTH)August 21, 2024 | finance.yahoo.comArch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug ToxinsAugust 2, 2024 | tmcnet.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)May 6, 2024 | globenewswire.comArch Therapeutics Secures $750K Prepayment for StockFebruary 8, 2024 | msn.comSee More Headlines ARTH Stock Analysis - Frequently Asked Questions How have ARTH shares performed this year? Arch Therapeutics' stock was trading at $0.1608 on May 30, 2026. Since then, ARTH stock has increased by 0.0% and is now trading at $0.1608. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings7/23/2020Today10/07/2026Fiscal Year End9/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees10Year Founded2006Profitability EPS (Trailing Twelve Months)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.98 million Net Margins-8,257.70% Pretax Margin-8,257.70% Return on EquityN/A Return on Assets-730.22% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.01 Sales & Book Value Annual Sales$80 thousand Price / Sales9.53 Cash FlowN/A Price / Cash FlowN/A Book Value($2.43) per share Price / Book-0.07Miscellaneous Outstanding Shares4,742,000Free Float4,529,000Market Cap$762.51 thousand OptionableNot Optionable Beta4.02 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:ARTH) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arch Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
